FibroGen Valuation
| FGEN Stock | MXN 7.94 0.89 12.62% |
At this time, the firm appears to be overvalued. FibroGen shows a prevailing Real Value of 6.44 per share. The current price of the firm is 7.94. Our model computes the value of FibroGen from reviewing the firm fundamentals such as Current Valuation of 21.87 B, profit margin of (2.94) %, and Operating Margin of (2.52) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that FibroGen's price fluctuation is relatively risky at this time. Calculation of the real value of FibroGen is based on 3 months time horizon. Increasing FibroGen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since FibroGen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of FibroGen Stock. However, FibroGen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.94 | Real 6.44 | Hype 7.94 | Naive 7.71 |
The intrinsic value of FibroGen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence FibroGen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of FibroGen helps investors to forecast how FibroGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of FibroGen more accurately as focusing exclusively on FibroGen's fundamentals will not take into account other important factors: FibroGen Total Value Analysis
FibroGen is currently anticipated to have takeover price of 21.87 B with market capitalization of 43.36 B, debt of 77.14 M, and cash on hands of 565.4 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the FibroGen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
21.87 B | 43.36 B | 77.14 M | 565.4 M |
FibroGen Investor Information
About 79.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 62.14. FibroGen had not issued any dividends in recent years. Based on the analysis of FibroGen's profitability, liquidity, and operating efficiency, FibroGen is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.FibroGen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. FibroGen has an asset utilization ratio of 30.41 percent. This suggests that the Company is making 0.3 for each dollar of assets. An increasing asset utilization means that FibroGen is more efficient with each dollar of assets it utilizes for everyday operations.FibroGen Ownership Allocation
FibroGen holds a total of 93.96 Million outstanding shares. The majority of FibroGen outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in FibroGen to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in FibroGen. Please pay attention to any change in the institutional holdings of FibroGen as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.FibroGen Profitability Analysis
The company reported the revenue of 235.31 M. Net Loss for the year was (290.02 M) with loss before overhead, payroll, taxes, and interest of (104.61 M).About FibroGen Valuation
Our relative valuation model uses a comparative analysis of FibroGen. We calculate exposure to FibroGen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of FibroGen's related companies.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.
8 Steps to conduct FibroGen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates FibroGen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct FibroGen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain FibroGen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine FibroGen's revenue streams: Identify FibroGen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research FibroGen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish FibroGen's growth potential: Evaluate FibroGen's management, business model, and growth potential.
- Determine FibroGen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate FibroGen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.